Plasma neutrophil gelatinase-associated lipocalin and long-term mortality in patients with acute heart failure and normal renal function
Impact
![Google Scholar](/xmlui/themes/Mirage2/images/uji/logo_google.png)
![Microsoft Academico](/xmlui/themes/Mirage2/images/uji/logo_microsoft.png)
Metadata
Show full item recordcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONThis resource is restricted
http://dx.doi.org/10.1016/j.ijcard.2016.03.089 |
Metadata
Title
Plasma neutrophil gelatinase-associated lipocalin and long-term mortality in patients with acute heart failure and normal renal functionAuthor (s)
Date
2016Publisher
ElsevierISSN
0167-5273; 1874-1754Bibliographic citation
MIÑANA, Gema, et al. Plasma neutrophil gelatinase-associated lipocalin and long-term mortality in patients with acute heart failure and normal renal function. International journal of cardiology, 2016, vol. 214, p. 51-53.Type
info:eu-repo/semantics/articlePublisher version
http://www.sciencedirect.com/science/article/pii/S0167527316305083Version
info:eu-repo/semantics/publishedVersionSubject
Abstract
Neutrophil gelatinase-associated lipocalin (NGAL) has emerged as a renal tubular marker for early renal dysfunction [1]. Recent studies highlighted its role in predicting acute kidney injury (AKI) and clinical outcomes ... [+]
Neutrophil gelatinase-associated lipocalin (NGAL) has emerged as a renal tubular marker for early renal dysfunction [1]. Recent studies highlighted its role in predicting acute kidney injury (AKI) and clinical outcomes in a wide range of cardiovascular diseases [2], [3], [4] and [5]. However, in heart failure (HF), conflicting results have been reported [4], [5], [6] and [7] and some ambiguities still prevail about the prognostic utility of NGAL beyond standard prognosticators and traditional renal biomarkers. We aimed to evaluate the independent ability of serum NGAL for predicting long-term mortality in patients admitted for acute HF (AHF).
We prospectively enrolled 206 patients consecutively admitted for AHF in the Cardiology Department of a third level centre from April 30th 2010 to March 1st 2011. We excluded patients with a diagnosis of pneumonia, sepsis, acute coronary syndrome or end-stage renal failure on dialysis or imminent need of dialysis. Demographic data, medical history, vital signs, 12-lead electrocardiogram, and laboratory data were determined on admission. Left ventricular ejection fraction (LVEF) was assessed by echocardiography during index hospitalization. Treatment was individualized following established guidelines [8]. [-]
Is part of
International journal of cardiology, 2016, vol. 214, p. 51-53.Rights
0167-5273/© 2016 Elsevier Ireland Ltd. All rights reserved.
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
This item appears in the folowing collection(s)
- MED_Articles [662]